Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 447

1.

Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers.

Zelek WM, Harris CL, Morgan BP.

Immunobiology. 2018 Dec;223(12):744-749. doi: 10.1016/j.imbio.2018.07.016. Epub 2018 Jul 20.

PMID:
30033110
2.

Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.

Zelek WM, Stott M, Walters D, Harris CL, Morgan BP.

Immunology. 2018 Nov;155(3):396-403. doi: 10.1111/imm.12982. Epub 2018 Jul 30.

3.

CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis.

Griffiths MR, Botto M, Morgan BP, Neal JW, Gasque P.

Immunology. 2018 Nov;155(3):346-355. doi: 10.1111/imm.12974. Epub 2018 Jul 11.

PMID:
29923617
4.

Complement system biomarkers in epilepsy.

Kopczynska M, Zelek WM, Vespa S, Touchard S, Wardle M, Loveless S, Thomas RH, Hamandi K, Morgan BP.

Seizure. 2018 Aug;60:1-7. doi: 10.1016/j.seizure.2018.05.016. Epub 2018 May 24.

PMID:
29857269
5.

Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis.

Michailidou I, Jongejan A, Vreijling JP, Georgakopoulou T, de Wissel MB, Wolterman RA, Ruizendaal P, Klar-Mohamad N, Grootemaat AE, Picavet DI, Kumar V, van Kooten C, Woodruff TM, Morgan BP, van der Wel NN, Ramaglia V, Fluiter K, Baas F.

Acta Neuropathol Commun. 2018 May 3;6(1):36. doi: 10.1186/s40478-018-0536-y.

6.

Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.

Collibee SE, Bergnes G, Muci A, Browne WF 4th, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ Jr, Morgan BP.

ACS Med Chem Lett. 2018 Feb 13;9(4):354-358. doi: 10.1021/acsmedchemlett.7b00546. eCollection 2018 Apr 12.

7.

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, Köhl J, Zillikens D, Ludwig RJ, Nimmerjahn F.

Front Immunol. 2018 Mar 16;9:535. doi: 10.3389/fimmu.2018.00535. eCollection 2018.

8.

Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.

Zelek WM, Watkins LM, Howell OW, Evans R, Loveless S, Robertson NP, Beenes M, Willems L, Brandwijk R, Morgan BP.

Mult Scler. 2018 Feb 1:1352458518758927. doi: 10.1177/1352458518758927. [Epub ahead of print]

PMID:
29421990
9.

Introduction to complement in health and disease: novel aspects and insights.

Morgan BP, Kavanagh D.

Semin Immunopathol. 2018 Jan;40(1):1-2. doi: 10.1007/s00281-017-0664-7. Epub 2018 Jan 8. No abstract available.

PMID:
29313086
10.

Complement system biomarkers in first episode psychosis.

Kopczynska M, Zelek W, Touchard S, Gaughran F, Di Forti M, Mondelli V, Murray R, O'Donovan MC, Morgan BP.

Schizophr Res. 2017 Dec 23. pii: S0920-9964(17)30764-8. doi: 10.1016/j.schres.2017.12.012. [Epub ahead of print]

11.

Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene.

Boshra H, Zelek WM, Hughes TR, Rodriguez de Cordoba S, Morgan BP.

J Immunol. 2018 Jan 1;200(1):327-335. doi: 10.4049/jimmunol.1701238. Epub 2017 Nov 22.

12.

Complement in the pathogenesis of Alzheimer's disease.

Morgan BP.

Semin Immunopathol. 2018 Jan;40(1):113-124. doi: 10.1007/s00281-017-0662-9. Epub 2017 Nov 13. Review. Erratum in: Semin Immunopathol. 2018 Sep 21;:.

13.

Effects of freezer storage time on levels of complement biomarkers.

Morgan AR, O'Hagan C, Touchard S, Lovestone S, Morgan BP.

BMC Res Notes. 2017 Nov 6;10(1):559. doi: 10.1186/s13104-017-2885-1.

14.

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis.

Loveless S, Neal JW, Howell OW, Harding KE, Sarkies P, Evans R, Bevan RJ, Hakobyan S, Harris CL, Robertson NP, Morgan BP.

Brain Pathol. 2018 Jul;28(4):507-520. doi: 10.1111/bpa.12546. Epub 2017 Jul 30.

PMID:
28707765
15.

Molecular cell biology of complement membrane attack.

Morgan BP, Boyd C, Bubeck D.

Semin Cell Dev Biol. 2017 Dec;72:124-132. doi: 10.1016/j.semcdb.2017.06.009. Epub 2017 Jun 21. Review.

16.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

17.

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.

Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y, Almo SC, Jacobson MP, Hua L, Xu Q, Gwaltney SL 2nd, Yee C, Harris J, Morgan BP, James J, Xu D, Hutchaleelaha A, Paulvannan K, Oksenberg D, Li Z.

ACS Med Chem Lett. 2017 Jan 23;8(3):321-326. doi: 10.1021/acsmedchemlett.6b00491. eCollection 2017 Mar 9.

18.

Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.

Granados-Durán P, López-Ávalos MD, Cifuentes M, Pérez-Martín M, Fernández-Arjona MD, Hughes TR, Johnson K, Morgan BP, Fernández-Llebrez P, Grondona JM.

Front Neurol. 2017 Mar 7;8:78. doi: 10.3389/fneur.2017.00078. eCollection 2017.

19.

High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients.

Mizuno M, Suzuki Y, Higashide K, Sei Y, Iguchi D, Sakata F, Horie M, Maruyama S, Matsuo S, Morgan BP, Ito Y.

PLoS One. 2017 Jan 3;12(1):e0169111. doi: 10.1371/journal.pone.0169111. eCollection 2017.

20.

The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease.

Morgan AR, Touchard S, O'Hagan C, Sims R, Majounie E, Escott-Price V, Jones L, Williams J, Morgan BP.

J Alzheimers Dis. 2017;56(1):25-36. doi: 10.3233/JAD-160889.

PMID:
27911318
21.

Highly selective inhibition of myosin motors provides the basis of potential therapeutic application.

Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7448-E7455. Epub 2016 Nov 4.

22.

Terminal complexes of the complement system: new structural insights and their relevance to function.

Morgan BP, Walters D, Serna M, Bubeck D.

Immunol Rev. 2016 Nov;274(1):141-151. doi: 10.1111/imr.12461. Review.

23.

Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.

Hakobyan S, Luppe S, Evans DR, Harding K, Loveless S, Robertson NP, Morgan BP.

Mult Scler. 2017 Jun;23(7):946-955. doi: 10.1177/1352458516669002. Epub 2016 Sep 9.

PMID:
27613120
24.

Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.

Hakobyan S, Harding K, Aiyaz M, Hye A, Dobson R, Baird A, Liu B, Harris CL, Lovestone S, Morgan BP.

J Alzheimers Dis. 2016 Sep 6;54(2):707-16. doi: 10.3233/JAD-160420.

PMID:
27567854
25.

Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.

Heurich M, Preston RJ, O'Donnell VB, Morgan BP, Collins PW.

Thromb Res. 2016 Sep;145:84-92. doi: 10.1016/j.thromres.2016.07.017. Epub 2016 Aug 2.

PMID:
27513882
26.

Complement is activated in progressive multiple sclerosis cortical grey matter lesions.

Watkins LM, Neal JW, Loveless S, Michailidou I, Ramaglia V, Rees MI, Reynolds R, Robertson NP, Morgan BP, Howell OW.

J Neuroinflammation. 2016 Jun 22;13(1):161. doi: 10.1186/s12974-016-0611-x.

27.

Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Towner LD, Wheat RA, Hughes TR, Morgan BP.

J Biol Chem. 2016 Jul 15;291(29):14927-38. doi: 10.1074/jbc.M115.708446. Epub 2016 May 19.

28.

Complement system activation contributes to the ependymal damage induced by microbial neuraminidase.

Granados-Durán P, López-Ávalos MD, Hughes TR, Johnson K, Morgan BP, Tamburini PP, Fernández-Llebrez P, Grondona JM.

J Neuroinflammation. 2016 May 21;13(1):115. doi: 10.1186/s12974-016-0576-9.

29.

Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma.

Williams PA, Tribble JR, Pepper KW, Cross SD, Morgan BP, Morgan JE, John SW, Howell GR.

Mol Neurodegener. 2016 Apr 6;11:26. doi: 10.1186/s13024-016-0091-6.

30.

Complement and Humoral Adaptive Immunity in the Human Choroid Plexus: Roles for Stromal Concretions, Basement Membranes, and Epithelium.

Moore GR, Laule C, Leung E, Pavlova V, Morgan BP, Esiri MM.

J Neuropathol Exp Neurol. 2016 May;75(5):415-28. doi: 10.1093/jnen/nlw017. Epub 2016 Mar 19.

31.

Editorial.

Morgan BP, Lachmann PJ Sir.

Immunobiology. 2016 Jun;221(6):699-700. doi: 10.1016/j.imbio.2016.02.005. Epub 2016 Feb 20. No abstract available.

PMID:
26979646
32.

Structural basis of complement membrane attack complex formation.

Serna M, Giles JL, Morgan BP, Bubeck D.

Nat Commun. 2016 Feb 4;7:10587. doi: 10.1038/ncomms10587.

33.

Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.

Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z.

Mol Immunol. 2016 Mar;71:10-22. doi: 10.1016/j.molimm.2016.01.003. Epub 2016 Jan 27.

PMID:
26826462
34.

Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Bahia El Idrissi N, Hakobyan S, Ramaglia V, Geluk A, Morgan BP, Das PK, Baas F.

Clin Exp Immunol. 2016 Jun;184(3):338-46. doi: 10.1111/cei.12767. Epub 2016 Mar 31.

35.

Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice.

Bloom AC, Collins FL, Van't Hof RJ, Ryan ES, Jones E, Hughes TR, Morgan BP, Erlandsson M, Bokarewa M, Aeschlimann D, Evans BAJ, Williams AS.

Bone. 2016 Mar;84:253-261. doi: 10.1016/j.bone.2015.12.014. Epub 2015 Dec 22.

36.

An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice.

Ruseva MM, Ramaglia V, Morgan BP, Harris CL.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14319-24. doi: 10.1073/pnas.1513698112. Epub 2015 Nov 2.

37.

Complementing the inflammasome.

Triantafilou M, Hughes TR, Morgan BP, Triantafilou K.

Immunology. 2016 Feb;147(2):152-64. doi: 10.1111/imm.12556. Review.

38.

Complement, a target for therapy in inflammatory and degenerative diseases.

Morgan BP, Harris CL.

Nat Rev Drug Discov. 2015 Dec;14(12):857-77. doi: 10.1038/nrd4657. Epub 2015 Oct 23. Review.

PMID:
26493766
39.

A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.

Challis RC, Araujo GS, Wong EK, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L, Morgan BP, Harris CL, Marchbank KJ, Goodship TH, Kavanagh D.

J Am Soc Nephrol. 2016 Jun;27(6):1617-24. doi: 10.1681/ASN.2015010100. Epub 2015 Oct 21.

40.

The role of complement in neurological and neuropsychiatric diseases.

Morgan BP.

Expert Rev Clin Immunol. 2015;11(10):1109-19. doi: 10.1586/1744666X.2015.1074039. Review.

PMID:
26389851
41.

Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial.

Kasanmoentalib ES, Valls Seron M, Morgan BP, Brouwer MC, van de Beek D.

J Neuroinflammation. 2015 Aug 15;12:149. doi: 10.1186/s12974-015-0372-y.

42.

Response to Comment on "Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis".

Giles JL, Choy E, van den Berg C, Morgan BP, Harris CL.

J Immunol. 2015 Jul 1;195(1):4. doi: 10.4049/jimmunol.1500968. No abstract available.

43.

The membrane attack complex as an inflammatory trigger.

Morgan BP.

Immunobiology. 2016 Jun;221(6):747-51. doi: 10.1016/j.imbio.2015.04.006. Epub 2015 Apr 30. Review.

PMID:
25956457
44.

The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.

Martínez-Barricarte R, Heurich M, López-Perrote A, Tortajada A, Pinto S, López-Trascasa M, Sánchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S.

Mol Immunol. 2015 Aug;66(2):263-73. doi: 10.1016/j.molimm.2015.03.248. Epub 2015 Apr 11.

45.

M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator.

Bahia El Idrissi N, Das PK, Fluiter K, Rosa PS, Vreijling J, Troost D, Morgan BP, Baas F, Ramaglia V.

Acta Neuropathol. 2015 May;129(5):653-67. doi: 10.1007/s00401-015-1404-5. Epub 2015 Mar 15.

46.

Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis.

Giles JL, Choy E, van den Berg C, Morgan BP, Harris CL.

J Immunol. 2015 Apr 1;194(7):3029-34. doi: 10.4049/jimmunol.1402956. Epub 2015 Feb 27.

47.

Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.

Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP.

Clin Exp Immunol. 2015 Jun;180(3):432-41. doi: 10.1111/cei.12595. Epub 2015 Apr 24.

48.

A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases.

Owen EP, Würzner R, Leisegang F, Rizkallah P, Whitelaw A, Simpson J, Thomas AD, Harris CL, Giles JL, Hellerud BC, Mollnes TE, Morgan BP, Potter PC, Orren A.

Mol Immunol. 2015 Mar;64(1):170-6. doi: 10.1016/j.molimm.2014.11.010. Epub 2014 Dec 19.

49.

A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.

Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S.

J Immunol. 2014 Dec 1;193(11):5567-75. doi: 10.4049/jimmunol.1402013. Epub 2014 Oct 29.

50.

Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration.

Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN.

J Immunol. 2014 Nov 15;193(10):4962-70. doi: 10.4049/jimmunol.1401613. Epub 2014 Oct 10.

Supplemental Content

Loading ...
Support Center